Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 3
2008 4
2009 5
2010 7
2011 5
2012 6
2013 1
2014 2
2015 2
2016 2
2017 2
2018 5
2019 3
2020 10
2021 8
2022 4
2023 3
2024 3
2025 7
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Free article. Clinical Trial.
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.
Bringhen S, Mina R, Cafro AM, Liberati AM, Spada S, Belotti A, Gaidano G, Patriarca F, Troia R, Fanin R, De Paoli L, Rossi G, Lombardo A, Bertazzoni P, Palumbo A, Sonneveld P, Boccadoro M. Bringhen S, et al. Among authors: de paoli l. Leukemia. 2018 Aug;32(8):1803-1807. doi: 10.1038/s41375-018-0024-1. Epub 2018 Jan 30. Leukemia. 2018. PMID: 29479061 Free article. Clinical Trial. No abstract available.
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework.
Boccadoro M, Belotti A, Bombaci F, Bringhen S, Buda G, Cafro AM, Caimmi M, Canali B, Canonico PL, Cavo M, Corso A, De Paoli L, Derudas D, Di Raimondo F, Galeone C, Gay F, Gentile M, Giuliani N, La Malfa P, Mercati R, Montefusco V, Musto P, Offidani M, Patriarca F, Petrucci MT, Riccaboni M, Tosi P, Zamagni E, Zambello R, Fiorentino F. Boccadoro M, et al. Among authors: de paoli l. BMC Cancer. 2025 Oct 31;25(1):1676. doi: 10.1186/s12885-025-15083-y. BMC Cancer. 2025. PMID: 41174511 Free PMC article.
Targetable Mutations in BRAF V600E-Negative Hairy-Cell Leukemia.
Santi A, Venanzi A, Pucciarini A, Schiavoni G, Naccari M, Albi E, De Paoli L, Intermesoli T, Lazzi S, Conte E, Mancini A, Falini B, Gozzetti A, D'Elia GM, Genua A, Tiacci E. Santi A, et al. Among authors: de paoli l. N Engl J Med. 2025 Apr 10;392(14):1451-1452. doi: 10.1056/NEJMc2500911. N Engl J Med. 2025. PMID: 40214038 No abstract available.
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy.
Conticello C, Del Fabro V, Romano A, Mele A, Mina R, Bringhen S, Orofino A, Antonioli E, Pulini S, De Paoli L, Za T, Cotzia E, Elia F, Casson A, Prete E, Citiso S, Liberatore C, Margiotta-Casaluci G, Fazio F, Morè S, Attucci I, Accardi F, Bongarzoni V, Mangiacavalli S, Rossi E, Mannina D, Garibaldi B, Rizzi R, Di Cecca M, Rossini B, Uccello G, Botta C, Leotta D, Vincelli D, Gentile M, Piciocchi A, Marsili G, Patriarca F, Zambello R, Musto P, Boccadoro M, Offidani M, Petrucci MT, Di Raimondo F. Conticello C, et al. Among authors: de paoli l. Ann Hematol. 2025 Oct;104(10):5223-5236. doi: 10.1007/s00277-025-06602-9. Epub 2025 Oct 7. Ann Hematol. 2025. PMID: 41055738 Free PMC article.
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone.
Liberatore C, Piciocchi A, Vincelli D, Mancuso K, Musso M, Buda G, Derudas D, Pavan L, Belotti A, Rago A, Paris L, Mina R, Conticello C, Rossi E, Skert C, Accardi F, Clissa C, Antonioli E, Farina F, Furlan A, Franceschini L, Mangiacavalli S, Cellini C, Aquino S, De Paoli L, Giuliani N, Vassallo F, Sargentini V, Soddu S, Bringhen S, Gentile M, Mele G, Patriarca F, More S, Fazio F, Musto P, Di Raimondo F, Cavo M. Liberatore C, et al. Among authors: de paoli l. Haematologica. 2026 Aug 1;111(8):2828-2831. doi: 10.3324/haematol.2025.300238. Epub 2026 Mar 19. Haematologica. 2026. PMID: 41852332 Free PMC article. No abstract available.
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data.
Martino EA, Pitino A, Offidani M, Della Pepa R, Gozzetti A, Bongarzoni V, Maroccia A, Amico V, Stefanoni P, Zamagni E, Terlizzi S, Derudas D, Palmieri S, Bianco R, Conticello C, Brunori M, Rago A, Lotti F, Fontana R, Sgherza N, Rossi E, Cafro AM, Febbo MA, Quinto AM, Cerchione C, Casaluci GM, Citro A, Califano C, Zambello R, Mangiacavalli S, Liberatore C, Buda G, De Magistris C, Amendola A, Vigna E, Bruzzese A, Barbieri E, Quaresima M, Roccotelli D, Farina F, Micozzi J, Vincelli ID, Tarantini G, Antonioli E, Aquino S, Maggi A, Lombardo A, Bertuglia G, Furlan A, Mele A, Annibali O, Cotzia E, Benvenuti P, De Paoli L, Barilà G, Morè S, De Stefano V, Di Raimondo F, Petrucci MT, Bolli N, Musto P, Neri A, Morabito F, Tripepi G, Gentile M. Martino EA, et al. Among authors: de paoli l. Haematologica. 2025 Mar 6;110(8):1875-1881. doi: 10.3324/haematol.2025.287325. Haematologica. 2025. PMID: 40761134 Free PMC article. No abstract available.
Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy : Correction to: annals of hematology.
Conticello C, Del Fabro V, Romano A, Mele A, Mina R, Bringhen S, Orofino A, Antonioli E, Pulini S, De Paoli L, Za T, Cotzia E, Elia F, Casson A, Prete E, Citiso S, Liberatore C, Margiotta-Casaluci G, Fazio F, Morè S, Attucci I, Accardi F, Bongarzoni V, Mangiacavalli S, Rossi E, Mannina D, Garibaldi B, Rizzi R, Di Cecca M, Rossini B, Uccello G, Botta C, Leotta D, Vincelli D, Gentile M, Piciocchi A, Marsili G, Patriarca F, Zambello R, Musto P, Boccadoro M, Offidani M, Petrucci MT, Di Raimondo F. Conticello C, et al. Among authors: de paoli l. Ann Hematol. 2025 Dec;104(12):6473-6474. doi: 10.1007/s00277-025-06713-3. Ann Hematol. 2025. PMID: 41225025 Free PMC article. No abstract available.
Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy.
Barilà G, Grassi A, Ruocco V, Liberatore C, Olivari E, Tinelli M, Fazio F, Morè S, Favero E, Cartia CS, Sgherza N, Conticello C, Mina R, Gherardini M, Mele G, Gentile M, Furlan A, Febbo MA, Del Giudice ML, Annibali O, Rossini B, Scomazzon E, Talarico M, Martino EA, De Magistris C, Fioritoni F, Cafro AM, Paris L, Pezzatti S, Della Pepa R, Boggione P, Pietrantuono G, Tomarchio V, Vassallo F, Pioltelli ML, Pisani F, Cagnetta A, De Paoli L, Buda G, Antonioli E, Galli M, Tosetto A, Musto P, Zamagni E, Patriarca F, Mangiacavalli S, Zambello R, Offidani M, Petrucci MT. Barilà G, et al. Among authors: de paoli l. Br J Haematol. 2026 Aug 18. doi: 10.1111/bjh.70751. Online ahead of print. Br J Haematol. 2026. PMID: 42610768
72 results